DIHYDROERGOTAMINE MESYLATE manufacturers
|
| | DIHYDROERGOTAMINE MESYLATE Basic information |
| | DIHYDROERGOTAMINE MESYLATE Chemical Properties |
| Melting point | 232°C | | refractive index | -20 ° (C=0.25, JP Method) | | storage temp. | Store at RT | | solubility | methanol: 21 mg/mL | | form | powder | | color | white | | Merck | 14,3174 | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. | | Major Application | pharmaceutical (small molecule) | | InChIKey | ADYPXRFPBQGGAH-WVVAGBSPSA-N | | SMILES | CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1C[C@H](CN2C)C(=O)N[C@]5(C)O[C@]6(O)N([C@@H](Cc7ccccc7)C(=O)N8CCC[C@@]68[H])C5=O)c34 | | CAS DataBase Reference | 6190-39-2(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 36 | | RIDADR | 1544 | | WGK Germany | 3 | | RTECS | KE7920000 | | HazardClass | 6.1(b) | | PackingGroup | III | | HS Code | 2939690000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Dermal
Acute Tox. 4 Inhalation |
| | DIHYDROERGOTAMINE MESYLATE Usage And Synthesis |
| Description | Dihydroergotamine mesylate (6190-39-2) is a full agonist at serotonin 5HT1B and 5HT1D receptors, IC50= 2 and 2.2 nM respectively1 and also at 5HT1A and 5HT1F receptors2. One of the oldest agents for treatment of migraine.3 Also acts as a potent vasoconstrictor and alpha-adrenergic antagonist.4 | | Chemical Properties | White to Off-White Solid | | Uses | α-Androgenic blocker with selective venoconstrictor properties. Also binds to serotonin 5HT1-receptors. Antimigraine. | | Uses | vasoconstrictor, antimigraine | | Uses | Agonist at vascular serotonin receptors; partial agonist at alpha-adrenergic and dopamine D2 receptors | | Definition | ChEBI: The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotens
on. | | Brand name | D.H.E. 45 (Valeant); Migranal (Valeant)
. | | Biological Activity | Partial α -adrenergic agonist. Partial D 2 dopaminergic receptor agonist. Competitive 5-HT antagonist. | | storage | Room temperature | | References | [1] ANNE S. LESAGE. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines[J]. British Journal of Pharmacology, 2009, 123 8: 1655-1665. DOI:10.1038/sj.bjp.0701766
[2] SILBERSTEIN S D. The pharmacology of ergotamine and dihydroergotamine.[J]. Headache, 1997, 37 Suppl 1: S15-25.
[3] STEPHEN D SILBERSTEIN Douglas C M. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.[J]. Headache, 2003, 43 2: 144-166. DOI:10.1046/j.1526-4610.2003.03034.x
[4] LIPTON R B. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.[J]. Headache, 1997, 37 Suppl 1: S33-41. |
| | DIHYDROERGOTAMINE MESYLATE Preparation Products And Raw materials |
|